They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and - in data presented by Eli Lilly (NYSE: LLY) - they have gone up against one another.
Lilly has announced detailed results from SURMOUNT-5, a Phase IIIb open-label clinical trial, evaluating the safety and efficacy of its own Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Novo Nordisk’s (NOV: N) Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes.
At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to Wegovy across the trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze